Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210046, China.
Bioorg Med Chem. 2012 Dec 15;20(24):6919-23. doi: 10.1016/j.bmc.2012.10.015. Epub 2012 Oct 23.
Two series of 8-aminomethylated derivatives were prepared by Mannich reaction of scutellarein (2) with appropriate aliphatic amines, alicyclic amines and formaldehyde. All the compounds were tested for their thrombin inhibition activity through the analyzation of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (FIB). The antioxidant activities of these target products were assessed by 1,1-diphenyl-2-picrylhydrazyl radical 2,2-diphenyl-1-(2,4,6-trinitrophenyl) hydrazyl (DPPH) assay using 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay method and the solubility were assessed by ultraviolet (UV). The results showed that morpholinyl aminomethylene substituent derivative (3d) demonstrated stronger anticoagulant activity, better water solubility and good antioxidant activity compared with scutellarein (2), which warrants further development as a agent for ischemic cerebrovascular disease treatment.
通过将白杨素(2)与合适的脂肪族胺、脂环族胺和甲醛进行曼尼希反应,制备了两系列 8-氨甲基衍生物。通过分析凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血时间(TT)和纤维蛋白原(FIB),测试了所有化合物的凝血酶抑制活性。使用 1,1-二苯基-2-苦基肼基自由基 2,2-二苯基-1-(2,4,6-三硝基苯基)肼基(DPPH)测定法和 3-(4,5)-二甲基噻唑(-z-y1)-3,5-二苯四唑基溴化(MTT)测定法评估了这些目标产物的抗氧化活性,并用紫外光(UV)评估了它们的溶解度。结果表明,与白杨素(2)相比,吗啉基氨甲叉取代衍生物(3d)具有更强的抗凝活性、更好的水溶性和良好的抗氧化活性,值得进一步开发作为治疗缺血性脑血管病的药物。